Factor XII - a drug target for safe interference with thrombosis and inflammation
Standard
Factor XII - a drug target for safe interference with thrombosis and inflammation. / Kenne, Ellinor; Renné, Thomas.
In: DRUG DISCOV TODAY, Vol. 19, No. 9, 01.09.2014, p. 1459-64.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Factor XII - a drug target for safe interference with thrombosis and inflammation
AU - Kenne, Ellinor
AU - Renné, Thomas
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Data from experimental animal models revealed an essential role for factor XII (FXII) in thrombotic occlusive diseases. In contrast to other blood coagulation factors, deficiency in the protease is not associated with abnormal bleeding from injury sites (hemostasis) in patients or in animals. Cumulatively, these findings suggest that FXII could be targeted as a new method of anticoagulation that is devoid of bleeding risks. An FXIIa-neutralizing antibody, 3F7, has been developed that inhibited thrombosis in an extracorporeal membrane oxygenation (ECMO) system as efficiently as heparin. However, in sharp contrast to heparin, 3F7 treatment was not associated with an increase in therapy-associated hemorrhage. In this review, we summarize current knowledge of FXII physiology and pharmacology.
AB - Data from experimental animal models revealed an essential role for factor XII (FXII) in thrombotic occlusive diseases. In contrast to other blood coagulation factors, deficiency in the protease is not associated with abnormal bleeding from injury sites (hemostasis) in patients or in animals. Cumulatively, these findings suggest that FXII could be targeted as a new method of anticoagulation that is devoid of bleeding risks. An FXIIa-neutralizing antibody, 3F7, has been developed that inhibited thrombosis in an extracorporeal membrane oxygenation (ECMO) system as efficiently as heparin. However, in sharp contrast to heparin, 3F7 treatment was not associated with an increase in therapy-associated hemorrhage. In this review, we summarize current knowledge of FXII physiology and pharmacology.
KW - Animals
KW - Antibodies
KW - Anticoagulants
KW - Disease Models, Animal
KW - Extracorporeal Membrane Oxygenation
KW - Factor XII
KW - Factor XIIa
KW - Hemorrhage
KW - Heparin
KW - Humans
KW - Inflammation
KW - Thrombosis
U2 - 10.1016/j.drudis.2014.06.024
DO - 10.1016/j.drudis.2014.06.024
M3 - SCORING: Journal article
C2 - 24993156
VL - 19
SP - 1459
EP - 1464
JO - DRUG DISCOV TODAY
JF - DRUG DISCOV TODAY
SN - 1359-6446
IS - 9
ER -